T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response
Authors
Moise, LeonardBiron, Bethany M.
Boyle, Christine M.
Yilmaz, Nese Kurt
Jang, Hyesun
Schiffer, Celia A.
Ross, Ted M.
Martin, William D.
De Groot, Anne S.
Document Type
Journal ArticlePublication Date
2018-09-05Keywords
H7N9T cell
T cell epitope
epitope prediction
hemagglutinin
immunoinformatics
influenza
molecular modeling
pandemic
structure-based vaccine design
vaccine
Biochemistry
Immunoprophylaxis and Therapy
Medicinal Chemistry and Pharmaceutics
Medicinal-Pharmaceutical Chemistry
Molecular Biology
Structural Biology
Virus Diseases
Metadata
Show full item recordAbstract
The delayed availability of vaccine during the 2009 H1N1 influenza pandemic created a sense of urgency to better prepare for the next influenza pandemic. Advancements in manufacturing technology, speed and capacity have been achieved but vaccine effectiveness remains a significant challenge. Here, we describe a novel vaccine design strategy called immune engineering in the context of H7N9 influenza vaccine development. The approach combines immunoinformatic and structure modeling methods to promote protective antibody responses against H7N9 hemagglutinin (HA) by engineering whole antigens to carry seasonal influenza HA memory CD4(+) T cell epitopes - without perturbing native antigen structure - by galvanizing HA-specific memory helper T cells that support sustained antibody development against the native target HA. The premise for this vaccine concept rests on (i) the significance of CD4(+) T cell memory to influenza immunity, (ii) the essential role CD4(+) T cells play in development of neutralizing antibodies, (iii) linked specificity of HA-derived CD4(+) T cell epitopes to antibody responses, (iv) the structural plasticity of HA and (v) an illustration of improved antibody response to a prototype engineered recombinant H7-HA vaccine. Immune engineering can be applied to development of vaccines against pandemic concerns, including avian influenza, as well as other difficult targets.Source
Hum Vaccin Immunother. 2018;14(9):2203-2207. doi: 10.1080/21645515.2018.1495303. Epub 2018 Sep 5. Link to article on publisher's site
DOI
10.1080/21645515.2018.1495303Permanent Link to this Item
http://hdl.handle.net/20.500.14038/48878PubMed ID
30015562Related Resources
Rights
Copyright © 2018 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.Distribution License
http://creativecommons.org/licenses/by-nc-nd/4.0/ae974a485f413a2113503eed53cd6c53
10.1080/21645515.2018.1495303
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2018 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.